Gioconda Di Carluccio
YOU?
Author Swipe
View article: Emerging Treatments Targeting the Tumor Microenvironment for Advanced Chondrosarcoma
Emerging Treatments Targeting the Tumor Microenvironment for Advanced Chondrosarcoma Open
Chondrosarcoma (ChS), a malignant cartilage-producing tumor, is the second most frequently diagnosed osseous sarcoma after osteosarcoma. It represents a very heterogeneous group of malignant chemo- and radiation-resistant neoplasms, accoun…
View article: Data from UPARANT: A Urokinase Receptor–Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and <i>In Vitro</i> and <i>In Vivo</i> Potency
Data from UPARANT: A Urokinase Receptor–Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and <i>In Vitro</i> and <i>In Vivo</i> Potency Open
This work is based on previous evidence showing that chemotactic sequence of the urokinase receptor (uPAR88-92) drives angiogenesis in vitro and in vivo in a protease-independent manner, and that the peptide Ac-Arg…
View article: Supplementary Methods, Figure Legends, Tables 1 - 4, Figure 1 from UPARANT: A Urokinase Receptor–Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and <i>In Vitro</i> and <i>In Vivo</i> Potency
Supplementary Methods, Figure Legends, Tables 1 - 4, Figure 1 from UPARANT: A Urokinase Receptor–Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and <i>In Vitro</i> and <i>In Vivo</i> Potency Open
PDF file - 234K, Table S1 - Stability in physiological solution of UPARANT. Table S2 - Blood Stability of UPARANT. Table S3. Proton Chemical Shifts, 3JNH-alphaCH Coupling Constants of UPARANT at 298 K. Table S4. Average backbone torsion an…
View article: Data from UPARANT: A Urokinase Receptor–Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and <i>In Vitro</i> and <i>In Vivo</i> Potency
Data from UPARANT: A Urokinase Receptor–Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and <i>In Vitro</i> and <i>In Vivo</i> Potency Open
This work is based on previous evidence showing that chemotactic sequence of the urokinase receptor (uPAR88-92) drives angiogenesis in vitro and in vivo in a protease-independent manner, and that the peptide Ac-Arg…
View article: Supplementary Methods, Figure Legends, Tables 1 - 4, Figure 1 from UPARANT: A Urokinase Receptor–Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and <i>In Vitro</i> and <i>In Vivo</i> Potency
Supplementary Methods, Figure Legends, Tables 1 - 4, Figure 1 from UPARANT: A Urokinase Receptor–Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and <i>In Vitro</i> and <i>In Vivo</i> Potency Open
PDF file - 234K, Table S1 - Stability in physiological solution of UPARANT. Table S2 - Blood Stability of UPARANT. Table S3. Proton Chemical Shifts, 3JNH-alphaCH Coupling Constants of UPARANT at 298 K. Table S4. Average backbone torsion an…
View article: Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors
Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors Open
Gastrointestinal stromal tumors (GISTs) are the most common malignant mesenchymal neoplasms of the gastrointestinal tract. The gold standard for the diagnosis of GISTs is morphologic analysis with an immunohistochemical evaluation plus gen…
View article: Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer
Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer Open
Several studies have ascertained that uPA and uPAR do participate in tumor progression and metastasis and are involved in cell adhesion, migration, invasion and survival, as well as angiogenesis. Increased levels of uPA and uPAR in tumor t…
View article: MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors
MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors Open
Advances in the use of targeted and immune therapies have revolutionized the clinical management of melanoma patients, prolonging significantly their overall and progression-free survival. However, both targeted and immune therapies suffer…
View article: Inhibiting Monocyte Recruitment to Prevent the Pro-Tumoral Activity of Tumor-Associated Macrophages in Chondrosarcoma
Inhibiting Monocyte Recruitment to Prevent the Pro-Tumoral Activity of Tumor-Associated Macrophages in Chondrosarcoma Open
Chondrosarcomas (CHS) are malignant cartilaginous neoplasms with diverse morphological features, characterized by resistance to chemo- and radiation therapies. In this study, we investigated the role of tumor-associated macrophages (TAM)s …
View article: Cyclization of the Urokinase Receptor-Derived Ser-Arg-Ser-Arg-Tyr Peptide Generates a Potent Inhibitor of Trans-Endothelial Migration of Monocytes
Cyclization of the Urokinase Receptor-Derived Ser-Arg-Ser-Arg-Tyr Peptide Generates a Potent Inhibitor of Trans-Endothelial Migration of Monocytes Open
The receptor for the urokinase-type plasminogen activator (uPAR) is a widely recognized master regulator of cell migration and uPAR88-92 is the minimal sequence required to induce cell motility. We and others have previously documented tha…